Table 2.

Ongoing phase 3 trials

Trial name	Study arms	Population	Primary end point
IMpactMF (NCT045761)	9.4 mg/kg IV every 3 weeks vs BAT∗	DIPSS intermediate-2 + MF, refractory to JAKi	OS
IMerge (NCT02598661)	7.5 mg/kg IV every 4 weeks vs placebo	IPSS low- to intermediate-risk MDS, transfusion dependence refractory to ESA	TI

^∗Hydroxyurea, thalidomide or analog, IFN, danazol, HMA, or chemotherapy; excludes JAKi.